Alpha Teknova, Inc. Reiterates Revenue Guidance for Fiscal 2024
May 13, 2024 at 09:01 pm
Share
Alpha Teknova, Inc. reiterated revenue guidance for fiscal 2024. The Company continues to anticipate total revenue of $35 million to $38 million for the fiscal year ending December 31, 2024 (?2024?), which assumes roughly 10% growth in Lab Essentials and the remaining revenue from Clinical Solutions.
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.
ALPHA TEKNOVA, INC. 
